YEWB Stock Overview
Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the People’s Republic of China and the United States.
Yew Bio-Pharm Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.0001|
|52 Week High||US$0.29|
|52 Week Low||US$0.0001|
|1 Month Change||-99.33%|
|3 Month Change||-99.91%|
|1 Year Change||-99.93%|
|3 Year Change||-99.88%|
|5 Year Change||-99.96%|
|Change since IPO||-99.99%|
Recent News & Updates
|YEWB||US Food||US Market|
Return vs Industry: YEWB underperformed the US Food industry which returned 0.1% over the past year.
Return vs Market: YEWB underperformed the US Market which returned -22.1% over the past year.
|YEWB Average Weekly Movement||n/a|
|Food Industry Average Movement||5.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: Insufficient data to determine YEWB's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine YEWB's volatility change over the past year.
About the Company
Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the People’s Republic of China and the United States. It offers traditional Chinese medicine (TCM) raw materials in the form of yew tree branches and leaves to manufacture TCM containing taxol. The company is also involved in processing and selling yew raw materials used in the manufacture of traditional Chinese medicine; growing and selling yew tree seedlings and mature trees, including potted miniature yew trees; manufacturing and selling furniture and handicrafts made of yew tree timber; selling agricultural products, such as yew candles, pine needle extracts, taxus cuspidate extracts, northeast yew extracts, and yew essential oil soaps; and selling wood ear mushroom.
Yew Bio-Pharm Group Fundamentals Summary
|YEWB fundamental statistics|
Is YEWB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YEWB income statement (TTM)|
|Cost of Revenue||US$28.89m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0078|
|Net Profit Margin||1.39%|
How did YEWB perform over the long term?See historical performance and comparison
Is YEWB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YEWB?
Other financial metrics that can be useful for relative valuation.
|What is YEWB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does YEWB's PE Ratio compare to its peers?
|YEWB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
MRGO Margo Caribe
GGRO.U Golden Growers Cooperative
DAAG Data Agro
YEWB Yew Bio-Pharm Group
Price-To-Earnings vs Peers: YEWB is good value based on its Price-To-Earnings Ratio (0x) compared to the peer average (6.2x).
Price to Earnings Ratio vs Industry
How does YEWB's PE Ratio compare vs other companies in the US Food Industry?
Price-To-Earnings vs Industry: YEWB is good value based on its Price-To-Earnings Ratio (0x) compared to the US Food industry average (18.2x)
Price to Earnings Ratio vs Fair Ratio
What is YEWB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||0.01x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate YEWB's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of YEWB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate YEWB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YEWB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Yew Bio-Pharm Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Food, Beverage & Tobacco industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yew Bio-Pharm Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Yew Bio-Pharm Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Yew Bio-Pharm Group's filings and announcements here.
How has Yew Bio-Pharm Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YEWB has high quality earnings.
Growing Profit Margin: YEWB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: YEWB's earnings have declined by 21.9% per year over the past 5 years.
Accelerating Growth: YEWB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: YEWB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Food industry (0.3%).
Return on Equity
High ROE: YEWB's Return on Equity (0.8%) is considered low.
Discover strong past performing companies
How is Yew Bio-Pharm Group's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: YEWB's short term assets ($13.9M) exceed its short term liabilities ($12.5M).
Long Term Liabilities: YEWB's short term assets ($13.9M) exceed its long term liabilities ($2.1M).
Debt to Equity History and Analysis
Debt Level: YEWB's net debt to equity ratio (19.2%) is considered satisfactory.
Reducing Debt: YEWB's debt to equity ratio has increased from 10.2% to 19.3% over the past 5 years.
Debt Coverage: YEWB's debt is well covered by operating cash flow (133.8%).
Interest Coverage: YEWB's interest payments on its debt are not well covered by EBIT (2x coverage).
Discover healthy companies
What is Yew Bio-Pharm Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Yew Bio-Pharm Group Dividend Yield vs Market|
|Company (Yew Bio-Pharm Group)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Food)||2.7%|
|Analyst forecast in 3 Years (Yew Bio-Pharm Group)||n/a|
Notable Dividend: Unable to evaluate YEWB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YEWB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YEWB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YEWB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as YEWB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Guifang Qi (60 yo)
Madame. Guifang Qi serves as Secretary of Bio-Pharm Group, Inc since December 15, 2013 and also serves as its Chief Executive Officer, Chief Financial Officer, President and Chairman of the Board since Jul...
CEO Compensation Analysis
|Guifang Qi's Compensation vs Yew Bio-Pharm Group Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$70k||US$70k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$70k||US$70k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$70k||US$70k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$70k||US$70k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$70k||US$70k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$52k||US$52k|
Compensation vs Market: Insufficient data to establish whether Guifang's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Guifang's compensation has been consistent with company performance over the past year.
Experienced Board: YEWB's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Yew Bio-Pharm Group, Inc.'s employee growth, exchange listings and data sources
- Name: Yew Bio-Pharm Group, Inc.
- Ticker: YEWB
- Exchange: OTCPK
- Founded: 2007
- Industry: Agricultural Products
- Sector: Food, Beverage & Tobacco
- Implied Market Cap: US$5.170k
- Shares outstanding: 51.70m
- Website: https://www.yewbiopharm.com
Number of Employees
- Yew Bio-Pharm Group, Inc.
- 9460 Telstar Avenue
- Suite 6
- El Monte
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|YEWB||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Jun 2013|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.